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History 
Angiogenesis, the term coined in 1935 1 means the deve-
lopment of new blood vessels from the pre-existing capillaries 
and venulae. It is fundamental for reproduction, development 
and reparation, when strict regulation and short duration pre-
vent the uncontrolled growth of neovascularization 2. In patho-
logical conditions, represented by solid tumors and a myriad of 
the neovascular diseases which involve retina, uvea and cor-
nea, the disbalanced regulation leads to the lasting, life- or 
sight-threatening vascular proliferation. 
Algire’s 3 observation that the tumors actively attract 
blood vessels, and Michealson’s 4 conclusion that a diffusible 
substance, factor X, present in the extravascular retina in vari-
ous concentrations, is necessary for retinal neovascularization, 
were the beacons along the path which lead to the right direc-
tion: development of the field of angiogenesis research fifty 
years ago, started by the pioneering work of Folkman et al. 5. 
Their hypothesis concerning the potential anticancer effects of 
angiogenesis inhibitors, based on the observation that the 
growth of solid tumors depends on their vascularization, 6 had 
been questioned until the isolation of a tumor factor  responsi-
ble for angiogenesis 7.  
Folkman’s laboratory introduced new methods necessary 
for the new field of research: corneal pocket assay, polymers 
for the sustained release of macromolecules, chorioallantoic 
membrane, and capillary endothelial cell culture 8, 9. Matrigel 
was added later 9. These new tools helped in the discovery of 
the first angiostimulators: basic and acid fibroblast growth fac-
tor (bFGF, aFGF), and angiogenin 10. Angiomodulators, most 
notably heparin, were added to the concept of angiogenesis 11. 
Heparin antidote, protamine, was the first angioinhibitor with 
the known structure 12. Then followed the discovery of a po-
tent angioinhibitory effect of heparin in the presence of corti-
sone, 13–15 and of two endogenous angioihibitors, angiostatin 16 
and endostatin 17. 
Growth factors 
A large number of molecules which stimulate or inhibit 
angiogenesis are known today. A key role among stimulators, 
especially in the eye, plays vascular endothelial growth factor 
(VEGF) 18, 19. Its inhibition has been used for the therapy of va-
rious diseases of different organs, from colorectal cancer to 
age related macular degeneration, just because they share pat-
hological angiogenesis in common. 
VEGF is a potent hemoatracatant and endothlial cell mi-
togen. Its angiogenic action is regulated by hypoxia 20. It is a 
dominant factor of ocular and general angiogenesis, being a 
perfect match for „Factor X“ postulated by Michaelson 4 as 
early as 1948. A single gene is coding for binding VEGF A, B, 
C. D to the tyrosin-kinase receptors VEGFR 1–3. Various iso-
forms of VEGF, created by alternate splicing, 21 enable this 
growth factor to act in more than one way: to stimulate angio-
genesis and vascular permeability, participate in organ deve-
lopment and vasculogenesis, maintain small fenestrated blood 
vessels, and protect nerve cells in the retina and 
elsewhere 22, 23.  
Basic fibroblast growth factor, although unable to promo-
te neither retinal nor choroidal neovascularization alone, can 
act in synergism with VEGF 24. Due to the lack of a signaling 
pathway for its release from cells and membranes, b FGF can 
act only upon their injury. Yet, its proangiogenic role is estab-
lished by the findings of high levels of b FGF in the vitreous 
of the eyes with proliferative diabetic retinopathy, and large 
tumors, as well as the rodent corneal neovascularization after 
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implantation of bFGF 25. Finally, a simultaneous inhibition of 
both b FGF and VEGF activities in vitro is more efficient than 
inhibition of only VEGF 26.   
Findings of the raised vitreous levels of erythropoietin 
in proliferative diabetic retinopathy, and inhibition of neo-
vascularization in the ischemic murine retina indicate that 
this, otherwise blood-forming substance has a role in angi-
ogenesis 27. This complex process is also influenced by an-
giopoietins, cyclooxygenases 28, platelet derived growth 
factor (PDF), hepatocyte growth factor (HGF), placenta 
growth factor (PlGF), transforming growth factor-beta 
(TGF-β), tumor necrosis factor-alpha (TNF-α), and interle-
ukines 29. 
Switch to angiogenic phenotype 
The sequence of events during angiogenesis is: burst 
of endothelial cells mitotic activity under the influence of 
an angiostimulator; creation of a break in the basement 
membrane; degradation of extracellular matrix; creation of 
a columnar structure through which blood starts to flow; 
termination of the process. For this to happen, a large num-
ber of receptors and ligands must be successively activated, 
while keeping a delicate balance of numerous stimulatory 
and inhibitory signals. Differently put, an angiogenic 
phenotype is achieved through a switch in the balance of 
angiogenesis stimulation and inhibition towards the former. 
As soon as the switch, usually a hypoxic stimulus, is turned 
on, the activity of angiogenic factors is up-regulated; 30 the 
shape of the cells is changed making cells succeptible to 
the action of angiogenic factors; 31–33 growth factors are re-
leased from their bound state; 34–36 pericytes, a barrier to 
angiogenesis, are lost and macrophages activated; 37–40 ge-
nes coding for angioinhibitors are inactivated; 41 proteolysis 
of large molecules to which angionhibitors are often bound 
is halted; soluble, decoy receptors, 42 like Fit-1, stop to bind 
angiostimulators, primarily VEGF; and notch signaling 43 
starts navigating activated cells through a matrix prepared 
by proteinases 44 and bi-directional transmembrane recep-
tors, integrins 45.  
Corneal avascularity 
One of the most useful ways towards understanding 
corneal angiogenesis is to study avascularity of the nomal 
cornea. The avascularity and easy accessability of cornea 
made it one of the most frequently used model of angioge-
nesis research 9, 46. As Cogan 47 nicely put it: „Any theory 
which claims to explain corneal neovasculogenesis must 
account for the absence of blood vessels in the normal cor-
nea. Unlike most other tissues, except probably cartilage, 
the cornea has no vessels and yet it is in immediate 
proximity of structures having blood vessels. No anatomic 
boundary separates the vascular limbus from the avascular 
cornea. An adequate explanation for this anatomic paradox 
would undoubtedly account for neovascularization of the 
cornea“. He believed that compactness of the normal cor-
nea presented a barrier, while corneal edema was a conditi-
on for the invasion of blood vessels 48. However, the shape 
of neovascularization induced by an isolated experimental 
corneal lesion led Campbell and Michaelson 49 to postulate 
the presence of a diffusible stimulator of blood vessel 
growth 49. Ashton and Cook 50, in a lengthy critical review, 
added one more possible cause, hypoxia, which acted per 
se or by inducing the activity of a diffusible factor. These 
statements are nowadays incorporated into the growing 
body of recently accumulated data on angiogenesis. 
All corneal layers participate in the maintenance of 
avascularity. The intact epithelium prevents both from cor-
neal edema and activation of stromal proteinases, active 
players along the cascade of angiogenesis. This layer also 
contains a high expression of soluble VEGF receptors, 51 
which bind and inactivate this potent mitogen of vascular 
endothelial cells 52. Consequently, antagonization of one of 
these soluble receptors by a tripeptide modulates angioge-
nesis 53. These decoy receptors are considered as the key 
players in maintenance of corneal avascularity. However, a 
recent observation of simultaneous suppression of corneal 
inflammation and neovascularization by netrin, 54 a mem-
ber of the family of proteins similar to laminin, previously 
thought to be involved in neurogenesis only, adds to the 
complexity of the proposed mechanism. These substances 
seem to originate from the superficial limbus, 55, 56 possibly 
from its stem cells, which are likely to have a task more 
complex than epithelial regeneration 57. The appearance of 
new blood vessels in cases with stem cell deficiency sup-
ports this line of thinking.  
Both epithelial cells and keratocytes show the 
expression of a potent angioinhibitor, thrombospondin 58, 59. 
Thrombospodins induce apoptosis of vascular endothelial 
cells and shield them from the bFGF activity 60. Both epit-
helium and endothelium of the rat cornea show the 
expression of pigment epithelium derived factor (PEDF), 
one of the most potent angioinhibitors, which is able to 
block a VEGF receptor 61. 
Matrix metaloproteinases (MMPs) are also expressed 
in various corneal cells. These zinc-dependent endopepti-
dases are able either to stimulate (MMP2, MMP14) or to 
inhibit (MMP3, MMP7) angiogenesis. The latter is achie-
ved by degradation of collagen XIII and plasminogen, lea-
ving active endostatin and angiostatin 62. It has recently be-
en shown that these enzymes can also have an anti-
inflammatory effect by changing a gene expression 63. 
In conclusion, corneal avascularity is maintained by 
homeostasis, which includes a well-known edema-
preventing balance between corneal swelling pressure and 
dehydration, as well as an equilibrum of numerous pro- and 
anti-angiogenic activities. 
Corneal neovascularization 
Corneal neovacularization (CONV) is formed when 
blood vessels from the limbus penetrate the avascular cor-
neal tissue (Figure 1). 
Subepithelial neovascularization is characterized by di-
rect arborization of blood vessels creating a pannus, which 
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splits the space between the epithelium and the Bowman’s 
membrane. Interstitial new blood vessels follow the direction 
of collagen fibers and grow in a brush-like fashion. The dee-
pest stromal neovascularization has an umbilical shape at 
first, and a membranous shape upon further growth 64. 
CONV is essentially a reparatory attempt in response to 
hypoxia created by infection, trauma, immune reaction, tu-
mor growth and stem cell loss. Accompanying processes and 
sequellae are: inflammation with cellular infiltration, edema, 
fibrous scarring, fatty deposit, and the loss of corneal immu-
ne privilege 60, 65. The price of this reparatory process, which 
occasionally saves the ocular globe, is often high, and can be 
expressed in visual and aesthetic loss. 
 
 
Fig. 1 – Corneal neovascularization. 
 
Trachoma and onchocerciasis, both characterized by 
dramatic CONV, are among the world’s most frequent cau-
ses of blindness. Their erradication needs measures that be-
long to economy rather that to angiogenesis research and 
therapy. But, about four percent of the population of the de-
veloped world also suffers from corneal neovascularization, 
mostly caused by herpes, with almost fifteen hundred thou-
sand new cases every year 66. The world statistics reports 
fourty thousand new cases of a drastic monocular visual loss 
or blindness per year 67. Other infective agents, like pseudo-
monas, chlamidia and fungi are less frequent causes of visual 
loss. The non-infective causes of CONV are: contact lens 
wear, ocular surface diseases, corneal graft rejection, eye 
drops with preservative, and trauma, especially chemical 
burns. The socioeconomic significance of CONV is not ne-
gligeble, and the new treatment modalities can lessen the 
burden carried by many individuals and the society. 
A key player in the ocular as well as corneal angioge-
nic cascade, like everywhere in the body, is VEGF. Its ric-
hest corneal resources are the epithelium, vascular endothe-
lial cells, macrophages, and fibroblasts 60. VEGF 
expression is significantly upregulated in inflammed and 
vascularized corneas 68. On the other hand, CONV stops 
when VEGF or its receptors are inhibited, or when signals 
for VEGF release are blocked 69, 70.  
Other minor factors involved in CONV are bFGF, released 
from basement membranes after injury; 34, 35, 71, PDGF, which 
stimulates VEGF transcription and brings pericytes to block 
apoptosis of new vascular buds; 72 and angiopoietin 29. Recent 
observations add epoxyeicosanoids to this list. These products of 
arachidonic acid metabolism control inflammatory and angioge-
nic response to injury, as a part of tissue and organ reparation 
and regeneration 73. 
Treatment of CONV 
Corticosteroids are still the mainstay of the therapy for 
CONV, sometimes aided by non-specific anti-inflammatory 
agents (NSAID) or cyclosporine. Physical methods include 
diathermy and photodynamic therapy, while transplantation of 
the limbus is beyond the scope of this review. 
Corticosteroids 
Corticosteroids act mainly against inflammation by pre-
vention of neutrophyl and macrophage accumulation (a hall-
mark of the late sensitivity reaction), their adhesion to the 
capillary endothelial cells, and formation of plasminogen activa-
tor 74. As Professor Claes Dohlman used to teach, this is why 
these medications helped the success of keratoplasty more than 
any surgical minutia. 
Antiangiogenic effects of corticosteroids do not depend on 
their gluco- or mineralo-corticoid  action. It seems to be achie-
ved by capillary basement membrane degradation 75. and is en-
hanced in the presence of heparin or its pentasacharide frag-
ment 14, 15. Unfortunately, these potent drugs have many side-
effects: they are associated with masking of the signs of bacteri-
al infection, progression of herpetic keratitis, and corneal melt if 
given later than a week after a chemical burn 76. Prolonged topi-
cal corticosteroid therapy may cause cataract 77 and glaucoma 78. 
Physical methods 
Photodynamic therapy can occlude larger blood vessels. It 
includes an intravenous injection and the use of argon or diode 
laser beam. It is a costly procedure, and the injected substance 
may be potentially harmful 79. 
Fine needle diathermy is quite easy to perform. Its best in-
dication is occlusion of one or few larger blood vessel prior to 
keratoplasty. A long-lasting effect in a bunch of small vessels is 
hard to achieve 80, 81.  
NSAID 
Topical NSAID inhibits angiogenesis in rat cornea 82. The-
se medications inhibit cyclooxygenases, and the consequence is 
a low level of prostaglandines produced from arachidonic acid. 
Their use is limited to the early stages of angiogenesis, until ac-
cumulation of a large quantity of VEGF is created. Occasional 
corneal melts have been reported during the use of NSAID. 
Even one drop of a preservative-free NSAID can result in inten-
se burning sensation.Therefore, caution and close observation 
are advised during their use 83–85.  
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Other medications 
 
Well-known angioinhibitors, cyclosporine A, 86 
methotrexate, 87 and tacrolimus 88 are mainly used as a sub-
stitution of corticosteroids, when a prolonged therapy after 
complicated keratoplasty is needed. Angioinhibitory action 
of thalidomide was unknown until it produced a tragic ef-
fect of inborn phocomelia 89, 90. Thalidomide has recently 
been found useful in the treatment of some malignant tu-
mors and uveitis, 91 but its use in CONV inhibition has be-
en checked only experimentally. Amiloride, a competive 
inhibitor of urokinase type-plasminogen activator system, 
has been shown to inhibit CONV in various experimental 
models, 92, 93 but without a clinical use. It is interesting to 
speculate whether the concentrations of this drug, widely 
used as a diuretic, can produce inconspicuous angioinhibi-
tion.  
Anti-VEGF therapy 
According to a recent meta analysis, 94 a few studies 
have shown that a VEGF blocade may compete with corti-
costeroids as the therapy of choice in cases of CONV. One 
of the jewels in the crown of a half a century long angioge-
nesis research 95 was USA Food and Drug Administartion 
(FDA) aproval of bevacizumab, a humanized monoclonal 
antibody against VEGF A (Avastin, Genentech, Roche), for 
the adjuvant treatment of metastatic colorectal cancer first, 
and some other solid malignant tumors later 96, 97. Intravit-
real injections of this drug have also revolutionarized the 
therapy of the wet form of age-related macular degenerati-
on, helped in the resolution of diffuse diabetic macular 
edema, and tried in various other ocular angiogenic disea-
ses 98, 99. However, the effect of topical bevacizumab in 
experimental CONV is only partial 100. It is possible that a 
humanized antibody cannot exert a full effect in 
experimental animals, while the inhbition of CONV in hu-
mans is significant 101–105. Subconjunctival and deep stro-
mal injections of bevacizumab have been given in hope for 
a better effect on the deep CONV 106. A better drug penet-
ration into the cornea has been tried with a fragment of be-
vacizumab, ranibizumab, which has a small molecule and a 
higher affinity for VEGF. Its effect, more on the vessel di-
ameter than on the involved surface area, has been only 
slighly better than the effect of bevacizumab 107. The 
cost/effectiveness ratio of these two drugs calls for further 
investigations 69. 
As previously stated, VEGF has more than one function. 
Possible late complications of huge doses of this drug given in 
oncology have not been excluded, but they are not within the 
scope of ophthalmology. However, corneal epithelial defects 
have been observed after topical application of bevacizu-
mab 103, 108–110. Pegabtanib, which binds only one VEGF iso-
form, offers less probability of complications which is 
unfortunately associated with a lesser effect 111. A novel thera-
peutic approach, VEGF trap, is the use of a soluble receptor mo-
lecule, aflibercept, that includes sequences from VEGFR 1 and 
2, and posseses a high binding affinity for VEGF-A and B, as 
well as for PlGF. Its prevents VEGF fom binding to its natural 
receptor and from promoting proliferation and migration of vas-
cular endothelial cells. The effect of VEGF trap lasts twice as 
long as the effect of VEGF blockade by monoclonal antibodi-
es 112, 113. 
Another approach is silencing of a gene for VEGF produc-
tion by one of ribonucleic acids, which inhibits the post-
transcrptional processing 114 and signals from tyrosin-kinase re-
ceptors 115.  
Targets other than VEGF 
Among the substances which have also been tried for 
CONV inhibition are topical netrins; 54 infliximab, a mono-
clonal antibody against TNF-α; 116 and doxycycline. 
Doxycycline is a tetracycline and a potent MMP inhibi-
tor 117. It aseems to be one of the smart drugs, and has 
recently been used in oncology, 118 cardiology, 119 and 
neurology 120. Its topical administration inhibits CONV in 
both experimental animals, 121 and in patients 122 by a 
MMP-independent mechanism 123. Doxycycline acts in 
synergism with bevacizumab, and can additionally protect 
the corneal epithelium from untoward effects of the lat-
ter 124. 
Conclusion 
It appears that the ocular anti-angiogenic therapy in 
the years ahead will find more use of vascular endothelial 
growth factor trap and integrins, and less of corticosteroids 
and monoclonal antibodies against vascular endothelial 
growth factor. Inexpensive therapy with a well-known 
drug, doxycycline, might be used when corneal neovascula-
rization is associated with disturbed epithelium. In the dis-
tant future treatment of corneal neovascularization will 
probably be based upon targeting a specific gene.  
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